2025 年 07 月 02 日 行业点评 看好/维持 医药 医药 《支持创新药高质量发展的若干措施》出台，创新药迎来高质量 发展机遇 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 24/7/1 24/9/12 24/11/24 25/2/5 25/4/19 25/7/1 ◼ 子行业评级 ◼ 推荐公司及评级 相关研究报告： 《2025 年医药行业投资策略：穿越风 雪，奔赴山海》-2025.01.06 证券分析师：谭紫媚 电话：0755-83688830 E-MAIL：tanzm@tpyzq.com 分析师登记编号：S1190520090001 证券分析师：郭广洋 电话：15601950558 E-MAIL：guoguangyang@tpyzq.com 分析师登记编号：S1190524100001 事件：国家医保局、国家卫生健康委于 2025 年 6 月 30 日联合印 发《支持创新药高质量发展的若干措施》（简称《措施》），从研发、支 付、临床应用等五大维度推出 16 项举措，着力破解创新药"研发难、 支付难、进院难"的核心痛点。 《措施》进一步完善了全链条支持创新药发展举措，为推动创新 药 ...

2025 年 05 月 14 日 行业日报 看好/维持 医药 医药 相关研究报告 <<太平洋医药日报（20250513）：诺和 诺德 Sogroya 三期临床成功>>-- 2025-05-14 <<生命科学上游系列研究（一）：供需 回暖，板块向上>>--2025-05-13 <<太平洋医药日报（20250509）：GSK 在研小分子linerixibat三期临床成 功>>--2025-05-13 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：张崴 电话： 太平洋医药日报（20250514）：默克匹米替尼拟纳入优先审评 ◼ 走势比较 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | E-MAIL：zhangwei@tpyzq.com 分析师登记编号：S1190524060001 报告摘要 市场表现： 2025 年 5 月 14 日，医药板块涨跌幅+0.10%，跑输沪深 300 指数 1.1 ...

Investment Rating - The industry rating is neutral, indicating that the expected overall return in the next six months will be between -5% and 5% compared to the CSI 300 index [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.74% on April 28, 2025, underperforming the CSI 300 index by 0.60 percentage points, ranking 15th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.83%), medical research outsourcing (+0.53%), and other biological products (+0.17%), while medical consumables (-1.98%), vaccines (-1.73%), and in vitro diagnostics (-1.65%) lagged behind [4]. - Novartis' application for a new indication for Pluvicto has been accepted by the Chinese National Medical Products Administration, targeting earlier-stage PSMA-positive mCRPC patients [5]. Summary by Sections Market Performance - On April 28, 2025, the pharmaceutical sector's performance was -0.74%, underperforming the CSI 300 index by 0.60 percentage points, with offline pharmacies and medical research outsourcing showing positive growth [4]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceutical industries: Neutral [3]. Company News - WuXi AppTec reported Q1 2025 revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, with net profit rising by 80.06% to 3.672 billion yuan [6]. - Hongbo Pharmaceutical reported Q1 2025 revenue of 169 million yuan, up 29.61%, with net profit increasing by 226.47% to 12 million yuan [6]. - Xingqi Eye Medicine reported Q1 2025 revenue of 536 million yuan, a 53.24% increase, with net profit soaring by 319.86% to 146 million yuan [6]. - Yingke Medical reported Q1 2025 revenue of 2.494 billion yuan, a 13.20% increase, with net profit rising by 48.08% to 353 million yuan [6].